Previous studies of immune response to Haemophilus influenzae after exacerbations of chronic obstructive pulmonary disease (COPD) have yielded contradictory results. Using homologous (infecting) strains and immunoassays to surface-exposed epitopes, we tested the hypothesis that adults with COPD make new antibodies to strain-specific, surface-exposed epitopes on H. influenzae after exacerbations. We collected clinical information, sputum, and serum monthly and during exacerbations from 81 patients with COPD over 56 months. Serum antibodies to H. influenzae after exacerbations associated with H. influenzae in sputum were detected with whole bacterial cell ELISA and bactericidal assays. An immune response to homologous H. influenzae 
Exacerbations contribute significantly to the morbidity and mortality associated with chronic obstructive pulmonary disease (COPD) (1) (2) (3) (4) . Nontypeable Haemophilus influenzae is the bacterial pathogen most commonly isolated from sputum during exacerbations (5, 6) . However, the role of H. influenzae in causing acute exacerbations is controversial, in part because of inconsistent results in studies of immune responses to H. influenzae (7) (8) (9) (10) (11) (12) (13) (14) (15) . Several limitations of these serologic studies have likely contributed to contradictory results (7) (8) (9) (10) (11) (12) (13) (14) (15) . Many previous studies compared antibodies in single sera obtained from patients with sera obtained from healthy control subjects rather than between paired sera obtained from individual patients before and after the exacerbation, potentially failing to detect significant immune responses (7, 8, 10, 11) . Several studies used a single or a small panel of laboratory strains of H. influenzae as an antigen instead of the strains recovered from sputum during the exacerbations (7-11, 14, 15) . In view of the considerable variation in the surface antigenic structure among H. influenzae strains, such a method fails to detect strain-specific immune responses (6, 12) . Furthermore, immunoassays used in several studies were not specific for antibodies to epitopes exposed on the bacterial surface, an approach that will not detect potentially protective antibodies in the background of antibodies to non-surfaceexposed or cross-reactive epitopes (7-11, 14, 15) . In this study, we used homologous (infecting) strains, immunoassays to detect antibodies to surface-exposed epitopes, and paired patient serum samples to test the hypothesis that adults with COPD make new antibodies to surface-exposed epitopes on H. influenzae after exacerbations.
Strains of H. influenzae that are new to a patient are associated with the development of an exacerbation (5) . Consistent with that observation, we further hypothesized that the immune response that develops after exacerbation to the homologous (infecting) strain will have limited ability to kill other (heterologous) H. influenzae strains (16) (17) (18) (19) (20) . Such a strain-specific immune response will protect against recurrent exacerbation due to the homologous strain but will leave the patient susceptible to exacerbations caused by antigenically unrelated heterologous strains.
To test these hypotheses, we conducted a study in which we obtained clinical information and serum and sputum samples monthly and during exacerbations from a cohort of patients with COPD. Serum antibodies to homologous and heterologous strains of H. influenzae were measured with whole bacterial cell ELISA and bactericidal assay. Some of the results of these studies have been previously reported in the form of an abstract (21, 22) .
METHODS

Study Design
The Human Studies Subcommittee of the Veterans Affairs Western New York Healthcare System approved the study protocol. All participants gave written informed consent. After initial recruitment, additional patients were recruited as needed to maintain active follow-up of 50 patients. To achieve this goal, a total of 81 patients with chronic bronchitis were enrolled between March 1994 and December 1998. Inclusion criteria have been described previously (5) . The patients were seen at the Buffalo Veterans Affairs Medical Center monthly and whenever there were symptoms suggestive of an exacerbation.
At each visit, clinical information and sputum and serum samples were collected. The criteria for defining an exacerbation have been described previously (5) .
Patient Samples and Bacterial Strains
The study personnel who processed the sputum samples were unaware of the clinical status of the patients. Sputum samples were spontaneously expectorated morning samples. Sputum samples were homogenized by incubation at 37ЊC for 15 minutes with an equal volume of 0.1% dithiothreitol (Sputolysin; Calbiochem, La Jolla, CA). Serial dilutions of homogenized sputum in phosphate-buffered saline (PBS) were plated on blood, chocolate, and MacConkey agar plates. Bacterial identification was performed by standard techniques. If H. influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae were present, up to 10 individual colonies of each bacterial species were isolated and saved as frozen stocks at Ϫ70ЊC. Serum was separated from 10 ml of blood collected at each clinic visit and stored in aliquots at Ϫ70ЊC.
Bacterial isolates from sputum were classified as potential pathogens or as normal flora. Potential pathogens included nontypeable H. influenzae, M. catarrhalis, S. pneumoniae, Pseudomonas aeruginosa, Staphylo-coccus aureus, and other gram-negative enteric rods. Other bacterial species were classified as normal flora. Sputum isolates of H. influenzae were typed as described previously, and each strain was categorized as preexisting or new (5) . A new strain was one that had not been isolated from sputum samples previously obtained from an individual patient. A preexisting strain was one that had been isolated from sputum obtained from a previous clinic visit.
Each H. influenzae strain was tested with two homologous patient sera to determine whether serum antibodies to the infecting strain develop after an exacerbation. The preexacerbation serum was obtained at a clinic visit before the exacerbation visit and the postexacerbation serum was obtained at least 4 weeks after the exacerbation visit.
Whole Bacterial Cell ELISA
The level of serum IgG to whole bacterial cell preparations of homologous isolates of H. influenzae was determined by ELISA as described previously for M. catarrhalis (23) . Preexacerbation and postexacerbation sera were tested simultaneously. The percentage change in optical density at 450 nm (OD 450 ) between postexacerbation and preexacerbation sera was calculated. To determine the level of a significant percentage change between postexacerbation and preexacerbation serum, 15 paired samples of sera obtained 2 months apart from subjects in the study clinic who had not experienced H. influenzae infection by sputum culture during that period were tested in ELISA with heterologous H. influenzae strains.
Bactericidal Assays
The presence of serum antibodies capable of antibody-mediated complement-dependent killing of strains of H. influenzae was determined by bactericidal assays. Bacteria grown to the midlogarithmic phase were diluted in PBS containing calcium and magnesium (PCGM) and volumes of 20 l added to wells of a 96-well plate. Ten-microliter aliquots of heat-inactivated (56ЊC for 30 minutes) serum were added to the wells (final serum concentration of 20%). An exogenous source of complement was prepared by depleting a healthy volunteer's serum of IgG by protein G chromatography (20) . After incubating the bacteria with the serum for 30 minutes, 5 l of complement was added (a final complement concentration of 10%), and the incubation continued for an additional 30 minutes at 37ЊC. Duplicate aliquots of the well contents were plated on chocolate agar and colony counts of surviving bacteria performed after overnight incubation. Control wells were performed simultaneously in each assay in which either complement or serum were omitted. A percentage kill was determined by calculating the colony count obtained after incubation with serum and complement as a percentage of the colony count obtained after incubation with serum alone and subtracting the value obtained from 100. A 50% kill was regarded as significant. Sera that demonstrated significant bacterial killing at 20% concentration were titrated with serial twofold dilution to determine the minimum bactericidal concentration.
Statistical Analysis
Patients who experienced at least one H. influenzae exacerbation were compared with patients who experienced no such exacerbations by unpaired t test for continuous data and by chi-square analysis for nominal data.
The unit of analysis was an exacerbation strain. The relationship of antibody response and whether the strain of H. influenzae was new to the patient was determined with generalized estimating equations to take into account that patients contributed more than one exacerbation strain (24) . An exchangeable correlation matrix was used with a binomial distribution and a logit link function. The coefficients of this regression are the logarithm of the odds ratio (OR). ORs of having an antibody response to H. influenzae when a new strain was present compared with when a preexisting strain was present were calculated. Similar analysis was performed to calculate the OR of having an ELISA response to H. influenzae when the strain was complement sensitive compared with when it was complement resistant.
The OR of finding a concomitant new pathogen when a new H. influenzae strain was present in the sputum compared with when a preexisting strain was present in the sputum was calculated, as described previously here, except the unit of analysis was an exacerbation.
RESULTS
Patient Demographics
Of the 81 patients, 35 had at least one exacerbation of COPD associated with H. influenzae isolation from sputum over 56 months for a total of 77 exacerbations. Table 1 compares these 35 patients with the 46 patients who did not experience a H. influenzae exacerbation. No differences were observed in the two groups in age, sex, racial distribution, tobacco consumption, and severity of airway obstruction. Patients with H. influenzae exacerbations had been observed for a significantly longer period in the study clinic and had had more exacerbations observed. Ten exacerbations were excluded from further study, three that were seen on the first clinic visit and seven that represented repeat visits for an exacerbation with the same strain isolated from sputum less than 4 weeks earlier. Therefore, 67 exacerbations in 33 patients (range of 1-7 per patient) were included in this study.
In four exacerbations, two strains of H. influenzae were isolated simultaneously. Two of these strains could not be studied further. One was not recoverable from frozen stock, and another demonstrated autoaggregation (clumping) in growth media. Therefore, 69 strains of H. influenzae were available for analysis. Molecular typing demonstrated that 36 strains were new to the patient, and 33 were preexisting strains.
Development of Serum Antibodies by Whole Bacterial Cell ELISA After Exacerbation
The 15 paired control samples from patients without H. influenzae infection demonstrated 0.4 Ϯ 8.6% (mean Ϯ 1 SD) change in OD 450 , with a 22.1% change representing the upper limit of the 99% confidence interval (CI). Therefore, an increase in OD 450 of more than 22.1% between the postexacerbation and preexacerbation sera was regarded as a significant serum IgG immune response to the infecting strain after an exacerbation.
ELISA assays detected a significant IgG response to 26 of the 69 (37.7%) strains (Figure 1) . Exacerbation strains of H. influenzae new to the patient were significantly more likely to be associated with an immune response by ELISA, which was seen with 21 of 36 (58.3%) new strains as compared with 5 of 33 (15.2%) preexisting strains (OR ϭ 7.7; 95% CI, 2.5 to 24.1; p Ͻ 0.001).
Development of Bactericidal Antibodies After Exacerbation
Bactericidal assays were attempted with all 69 strains and were successfully performed with 50 strains. One strain demonstrated autoaggregation in PBS. Eighteen strains (10 new and 8 preexisting) were killed by 10% complement in the absence of serum antibodies. This complement sensitivity was seen with three complement sources: two IgG-depleted normal human sera and one hypogammaglobulinemic serum.
Development of bactericidal antibodies to the homologous strain after exacerbation was demonstrated if the postexacerbation serum was bactericidal and the corresponding preexacerbation serum was not bactericidal at 20% concentration or if there was a two-dilution (fourfold) increase in titer between the preexacerbation and the postexacerbation serum. A bactericidal antibody response after exacerbation was seen with 23 of 50 strains (46%) (Figures 2A and 2B) . Exacerbation strains of H. influenzae new to the patient were significantly more likely to be associated with development of bactericidal antibodies, which was seen with 18 of 26 (69.2%) new strains as compared with 5 of 24 (20.8%) preexisting strains (OR ϭ 8.7; 95% CI, 2.7 to 28.0; p Ͻ 0.001).
Bactericidal antibodies to the homologous infecting strain were not detected in 25 of the 26 (96.2%) preexacerbation sera when the H. influenzae strain was new to the patient. However, preexacerbation sera were bactericidal for 18 of 24 (75%) preexisting H. influenzae strains.
SUBJECTS WHO EXPERIENCED AT LEAST ONE HAEMOPHILUS INFLUENZAE EXACERBATION COMPARED WITH THOSE WHO HAD NONE OBSERVED DURING THE 56 MONTHS OF FOLLOW-UP IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE STUDY CLINIC
Development of either ELISA or Bactericidal Immune Response
Concordant results were seen in 42 of 50 (84%) instances when both bactericidal and ELISA assays were completed with a strain and set of sera. 
Strain Specificity of the Immune Response
To determine the strain specificity of postexacerbation bactericidal antibodies, 10 postexacerbation sera from 10 patients that killed homologous strains were studied. Each serum was tested with nine heterologous H. influenzae strains in bactericidal assays at 20% concentration for a total of 90 assays. If a postexacerbation serum killed a heterologous strain, the corresponding preexacerbation serum was also tested with the heterologous strain. Postexacerbation sera were bactericidal in 17 of the 90 (18.9%) assays with heterologous strains. Six of the 17 corresponding preexacerbation sera were also bactericidal for the heterologous strain. Therefore, new bactericidal antibodies that developed after an exacerbation killed in 11 of 90 (12.2%) assays with heterologous strains. Of the 10 postexacerbation sera tested, 4 killed only the homologous strain, 4 killed one, 1 killed three, and 1 killed four heterologous strains. Therefore, 8 of the 10 postexacerbation sera were highly strain specific, whereas 2 demonstrated partial strain specificity.
Simultaneous Isolation of Other Bacterial Pathogens from Sputum
For this analysis, two exacerbations that had a new and a preexisting strain of H. influenzae simultaneously isolated were classified as exacerbations associated with new strains of H. influenzae.
Other respiratory pathogens were simultaneously isolated from sputum in 1 of the 36 exacerbations with new strains and with 10 of the 31 exacerbations associated with preexisting strains of H. influenzae (Table 2) . Furthermore, the other bacterial pathogen isolated was new to the patient, as determined by molecular typing in 9 of the 11 instances (Table 2 ). Exacerbations with a preexisting H. influenzae strain were significantly more frequently associated with a concomitant pathogen new to the patient than exacerbations with a new H. influenzae strain (OR ϭ 14.9; 95% CI, 1.6 to 138.3; p ϭ 0.018).
DISCUSSION
In this study, we have demonstrated that after an exacerbation of COPD associated with a H. influenzae strain isolated from sputum, there is development of serum antibodies to the infecting strain in the majority of instances when that strain was newly acquired by the patient. These antibodies are directed to antigens that are exposed on the bacterial surface and are therefore potentially protective. Indeed, serum bactericidal antibodies are associated with protection from otitis media due to H. influenzae (16) . In addition, the immune response that develops is quite specific to the homologous strain and therefore likely will not protect against infectious exacerbations by other strains of H. influenzae with a different antigenic structure. Therefore, these observations substantiate the role of H. influenzae in a proportion of exacerbations and help explain a mechanism for recurrent exacerbations with H. influenzae in COPD.
After immunization with whole bacterial cells in animal models, a substantial proportion of bactericidal antibodies that develop to H. influenzae are to a major outer membrane protein P2 (19, 25) . The same was observed for human bactericidal antibodies that developed after exacerbations of COPD in two patients from our study (20) . Extracellular portions of outer membrane protein P2 show a high degree of sequence variability among strains of H. influenzae (26) (27) (28) (29) . We speculate that the strain-specific immune response observed in this study is directed at heterogeneous surface epitopes on outer membrane protein P2 and other surface antigens of H. influenzae.
Exacerbations of COPD associated with preexisting strains of H. influenzae were not associated with an immune response in the majority of instances, suggesting that other infectious or noninfectious factors caused these exacerbations. Other bacterial pathogens that were new to the patient were isolated in eight of these exacerbations and likely induced the increased symptoms. Viruses and atypical bacteria are associated with exacerbations of COPD and were not investigated in this study (30, 31) . Changes in the surface antigenic structure in vivo in a preexisting strain of H. influenzae may allow it to escape the immune response and induce an exacerbation, another possible explanation for these exacerbations (25, (32) (33) (34) .
The absence of a host immune response to complement sensitive strains of H. influenzae is an intriguing and novel observation. We speculate that either because of their sensitivity to complement or because of other virulence determinants associated with complement sensitivity, these strains colonize the mucosal surface rather than invade the bronchial mucosa. Therefore, they may fail to elicit a humoral immune response. This observation needs further investigation to provide valuable insight into the virulence mechanisms of nontypeable H. influenzae.
Limitations of our study include the reliance on sputum samples to define infection with their low sensitivity and specificity. This study did not assay the mucosal immune response, which may be important, especially with complement-sensitive strains of H. influenzae (9, 10, 35) . Simultaneous study of viral and atypical bacterial infection would have provided a more comprehensive assessment of the infectious etiology of exacerbations.
We have recently demonstrated that acquisition of new strains of bacterial pathogens in COPD is associated with a substantial increase in risk of exacerbation (5) . Bacterial pathogens are isolated in significant concentrations from bronchoscopic samples during acute exacerbations (36) (37) (38) (39) . Neutrophilic airway inflammation is associated with isolation of bacterial pathogens from sputum (40, 41) . This study lends another line * A new strain was one that had not been previously isolated from sputum from that patient since enrollment in the study clinic, and a preexisting strain was one that had been previously isolated from sputum from that patient.
of evidence that bacteria indeed cause a substantial proportion of exacerbations of COPD. Recurrent exacerbations with H. influenzae in COPD have been ascribed previously to periodic increases in bacterial concentration in the airways. This study supports a new mechanistic explanation for recurrent exacerbations with H. influenzae in these patients. Specifically, patients make strain-specific antibodies after exacerbations, leaving the host susceptible to reinfection by other strains of H. influenzae. 
